3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Recurrence
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, B-Cell
1
Hodgkin Disease
1
Interventions
Cyclophosphamide
13
Prednisone
10
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
9
Doxorubicin
9
Vincristine
8
Azacitidine
6
romidepsin
5
Gemcitabine
5
Brentuximab Vedotin
5
fludarabine
4
Etoposide
4
Dexamethasone
4
pembrolizumab
3
belinostat
3
Lenalidomide
3
Biopsy
3
10-propargyl-10-deazaaminopterin
3
tazemetostat
2
ruxolitinib
2
ixazomib
2
duvelisib
2
Nivolumab
2
Bendamustine Hydrochloride
2
venetoclax
1
tislelizumab
1
thymoglobulin
1
spartalizumab
1
somatostatin, cyclic hexapeptide(Phe-Phe-Trp-Lys-Thr-Phe)-
1
sodium-iodide symporter
1
sintilimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, T-Cell, Peripheral
×
AFM13
×
1 year
×
Clear all
NCT05883449
2025-08-20
LuminICE-203
Affimed GmbH
Phase 2
Terminated
25 enrolled
21 charts